179 related articles for article (PubMed ID: 31381231)
1. Subcutaneous methotrexate versus oral form for the treatment and prophylaxis of chronic plaque psoriasis.
Attwa EM; Elkot RA; Abdelshafey AS; Hafez AR
Dermatol Ther; 2019 Sep; 32(5):e13051. PubMed ID: 31381231
[TBL] [Abstract][Full Text] [Related]
2. Comparison of overall efficacy and safety of oral versus subcutaneous methotrexate in severe psoriasis.
Dogra S; Singh N; Kumar S; Narang T; Handa S
Dermatol Ther; 2022 Aug; 35(8):e15656. PubMed ID: 35730664
[TBL] [Abstract][Full Text] [Related]
3. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
[TBL] [Abstract][Full Text] [Related]
4. Analysis of factors influencing target PASI responses and side effects of methotrexate monotherapy in plaque psoriasis: a multicenter study of 1521 patients.
Erduran F; Emre S; Hayran Y; Adışen E; Polat AK; Üstüner P; Öztürkcan S; Öztürk P; Ermertcan AT; Selçuk LB; Aksu EK; Akbaş A; Kalkan G; Demirseren D; Kartal SP; Topkarcı Z; Kılıç A; Yaldız M; Aytekin S; Hızlı P; Gharehdaghi S; Borlu M; Işık L; Botsalı BR; Solak EÖ; Albayrak H; Gönülal M; Balcı DD; Polat M; Daye M; Ataseven A; Yıldız S; Özer İ; Zorlu Ö; Doğan S; Erdemir VA; Dikicier BS
Arch Dermatol Res; 2024 May; 316(6):278. PubMed ID: 38796658
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of methotrexate (0.3 mg/kg/week) versus a combination of methotrexate (0.15 mg/kg/week) with cyclosporine (2.5 mg/kg/day) in chronic plaque psoriasis: A randomised non-blinded controlled trial.
Singh SK; Singnarpi SR
Indian J Dermatol Venereol Leprol; 2021; 87(2):214-222. PubMed ID: 33769732
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study.
Dogra S; Krishna V; Kanwar AJ
Clin Exp Dermatol; 2012 Oct; 37(7):729-34. PubMed ID: 22830389
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Subcutaneous Methotrexate in Chronic Plaque Psoriasis.
Yesudian PD; Leman J; Balasubramaniam P; Macfarlane AW; Al-Niaimi F; Griffiths CE; Burden AD; Warren RB
J Drugs Dermatol; 2016 Mar; 15(3):345-9. PubMed ID: 26954320
[TBL] [Abstract][Full Text] [Related]
8. Relapse in psoriasis with two different tapering regimens of methotrexate: a randomized open-label controlled study.
Singh SK; Rai T
Indian J Dermatol Venereol Leprol; 2015; 81(2):144-7. PubMed ID: 25751329
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the clinical efficacy of subcutaneous vs. oral administration of methotrexate in patients with psoriasis vulgaris: a randomized controlled trial.
Choonhakarn C; Chaowattanapanit S; Julanon N; Limpawattana P
Clin Exp Dermatol; 2022 May; 47(5):942-948. PubMed ID: 35015903
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
Papp K; Thaçi D; Marcoux D; Weibel L; Philipp S; Ghislain PD; Landells I; Hoeger P; Kotkin C; Unnebrink K; Seyger M; Williams D
Lancet; 2017 Jul; 390(10089):40-49. PubMed ID: 28478975
[TBL] [Abstract][Full Text] [Related]
12. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Warren RB; Mrowietz U; von Kiedrowski R; Niesmann J; Wilsmann-Theis D; Ghoreschi K; Zschocke I; Falk TM; Blödorn-Schlicht N; Reich K
Lancet; 2017 Feb; 389(10068):528-537. PubMed ID: 28012564
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France.
Tournier A; Khemis A; Maccari F; Reguiai Z; Bégon E; Fougerousse AC; Amy de la Breteque M; Beneton N; Parier J; Boyé T; Avenel-Audran M; Girard C; Pallure V; Perrot JL; Bastien M; Mahé E; Beauchet A;
Ann Dermatol Venereol; 2019 Feb; 146(2):106-114. PubMed ID: 30704943
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry.
Klein A; Kaul I; Foeldvari I; Ganser G; Urban A; Horneff G
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1349-56. PubMed ID: 22649024
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis.
Chládek J; Grim J; Martínková J; Simková M; Vanìèková J; Koudelková V; Noièková M
Br J Clin Pharmacol; 2002 Aug; 54(2):147-56. PubMed ID: 12207634
[TBL] [Abstract][Full Text] [Related]
16. Weekly vs. daily administration of oral methotrexate (MTX) for generalized plaque psoriasis: a randomized controlled clinical trial.
Radmanesh M; Rafiei B; Moosavi ZB; Sina N
Int J Dermatol; 2011 Oct; 50(10):1291-3. PubMed ID: 21950300
[TBL] [Abstract][Full Text] [Related]
17. Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.
Bae SH; Yun SJ; Lee JB; Kim SJ; Won YH; Lee SC
J Dermatol; 2016 Jun; 43(6):643-9. PubMed ID: 26598783
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial.
Braun J; Kästner P; Flaxenberg P; Währisch J; Hanke P; Demary W; von Hinüber U; Rockwitz K; Heitz W; Pichlmeier U; Guimbal-Schmolck C; Brandt A;
Arthritis Rheum; 2008 Jan; 58(1):73-81. PubMed ID: 18163521
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: a comparative study.
Ranjan N; Sharma NL; Shanker V; Mahajan VK; Tegta GR
J Dermatolog Treat; 2007; 18(5):295-300. PubMed ID: 17852635
[TBL] [Abstract][Full Text] [Related]
20. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis.
Chládek J; Simková M; Vanecková J; Hroch M; Chládkova J; Martínková J; Vávrová J; Beránek M
Eur J Clin Pharmacol; 2008 Apr; 64(4):347-55. PubMed ID: 18163165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
